[Cardiovascular actions of a standardized polyphenol concentrate on patients undergoing coronary bypass grafting: a randomized, double-blind, placebo-controlled study].
In this study the authors analyzed the action of Flavon Max product on the cardiovascular system of patients with severe coronary disease. Two randomized, double-blind, placebo controlled trials were carried out using impedance-cardiography, arteriography, vascular Doppler and biochemical laboratory methods. The results demonstrate that Augmentation Index measured with arteriography and C reactive protein (CRP) levels were significantly ameliorated after 2 x 2 months Flavon Max therapy. In conclusion, this product is beneficial as adjuvant in the treatment of atherosclerotic coronary disease.
Galajda
Zoltán
Z
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Kardiológiai Intézet, Szívsebészeti Központ, Debrecen. galajda@dote.hu
Dér
Henrietta
H
Balogh
Emese
E
Szentkirályi
István
I
Tóth
Zsuzsa
Z
Soltész
Pál
P
Szentmiklósi
A József
AJ
D000328:Adult; D000368:Aged; D000792:Angiography; D002097:C-Reactive Protein / Q000378:metabolism; D002307:Cardiography, Impedance; D002317:Cardiovascular Agents / Q000494:pharmacology*; D001026:Coronary Artery Bypass; D004311:Double-Blind Method; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010636:Phenols / Q000494:pharmacology*; D059808:Polyphenols; D013997:Time Factors; D017539:Tunica Intima / Q000473:pathology; D017540:Tunica Media / Q000473:pathology; D017535:Ulnar Artery / Q000473:pathology; D018608:Ultrasonography, Doppler
D002317:Cardiovascular Agents; D005419:Flavonoids; D010636:Phenols; D059808:Polyphenols; D002097:C-Reactive Protein